Footnotes

• Presented at This work was presented in part at the 2017 annual meeting of the American Association of Hip and Knee Surgeons, Dallas, TX, 2–5 November 2017; and the 2018 annual meeting of the American Academy of Orthopaedic Surgeons, New Orleans, 6–10 March 2018.

• Funding The American Association of Hip and Knee Surgeons provided financial support for the cost of the statistical analysis.

• Disclaimer All authors or contributors to the Clinical Practice Guideline have provided a disclosure statement in accordance with the publicly available AAOS Orthopaedic Disclosure Program. All authors and contributors attest none of the disclosures present are relevant to the Clinical Practice Guidelines.

• Competing interests None declared.

• Provenance and peer review Not commissioned; externally peer reviewed.

• Author note Tranexamic acid is a drug described in this Clinical Practice Guideline that has only been approved by the Food and Drug Administration (FDA) for dental bleeding prophylaxis in patients with hemophilia and menorrhagia. According to the FDA, it is the prescribing physician's responsibility to ascertain the FDA clearance status for all medications prior to use in a clinical setting.